SCHEDULE: Kenneth Rickel Discloses 5.7% Stake in Hepion Pharmaceuticals

Kenneth Rickel has filed a Schedule 13G, reporting beneficial ownership of 5,250,000 shares, representing 5.7% of Hepion Pharmaceuticals' outstanding common stock.

Summary

• Kenneth Rickel has reported beneficial ownership of 5,250,000 shares of Hepion Pharmaceuticals, Inc. common stock.
• This holding represents 5.7% of the company's outstanding common stock.
• The reported shares include 2,000,000 shares issuable upon the exercise of warrants.
• The total outstanding shares of Common Stock as of August 10, 2026, were 90,219,317.
• Rickel has sole voting power and sole dispositive power over these shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not overwhelming ownership stake by a key individual, with no immediate negative indicators.

Positives

• Significant ownership stake by Kenneth Rickel, indicating potential long-term commitment or strategic interest.
• The filing clarifies the ownership structure and potential voting influence of a key individual.
• The inclusion of shares issuable upon warrant exercise provides a fuller picture of potential ownership.

Negatives

• No explicit negative information is present in this Schedule 13G filing.

Risks

• Concentration of ownership, while not excessive, could influence corporate decisions.
• The potential exercise of warrants could lead to further dilution if not managed carefully.

Future Outlook

This filing does not contain forward-looking statements or specific future guidance from the company. It is a disclosure of ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders. This filing indicates a substantial, but not controlling, stake in Hepion Pharmaceuticals, a biotechnology company, by Kenneth Rickel.

Comparison to Industry Standards

• Ownership stakes of 5-10% are common for significant investors in the biotechnology sector, often held by venture capital firms, strategic partners, or key individuals.
• The inclusion of shares from warrant exercises is a standard practice in reporting potential ownership, reflecting the dilutive effect of such instruments.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant ownership position, which may influence market perception.
• Management: May need to consider the perspective of a substantial shareholder in strategic decision-making.

Next Steps

• Monitor future filings for any changes in Kenneth Rickel's ownership stake.
• Observe any potential strategic actions or influence by Kenneth Rickel on Hepion Pharmaceuticals' corporate governance or strategy.

Key Dates

Keywords

Hepion Pharmaceuticals, Schedule 13G, Beneficial Ownership, Kenneth Rickel, Warrants, Common Stock, Ownership Stake